Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.44 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29545868 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1BLMTDP1PMP22 | |
| Water SCHEMBL6479622 | 0.98 | KDM4E (0.44) | KDM4EALDH1A1BLMTDP1PMP22 | |
| Hydrochloric Acid SCHEMBL28868510 | 0.98 | KDM4E (0.44) | KDM4EALDH1A1BLMTDP1PMP22 | |
| Hydrochloric Acid SCHEMBL30431695 | 0.98 | KDM4E (0.44) | KDM4EALDH1A1BLMTDP1PMP22 | |
| SCHEMBL9435433 | 0.89 | RPS6KA3 (0.41) | KDM4EALDH1A1BLMTDP1PMP22 | |
| Pterine SCHEMBL1512995 | 0.82 | HSD17B10 (0.46) | KDM4EALDH1A1PMP22HSD17B10MEN1 | |
| SCHEMBL30572345 | 0.80 | GDA (0.44) | KDM4EALDH1A1BLMTDP1PMP22 | |
| SCHEMBL340668 | 0.80 | GDA (0.44) | KDM4EALDH1A1BLMTDP1PMP22 | |
| SCHEMBL3961933 | 0.80 | GDA (0.44) | KDM4EALDH1A1BLMTDP1PMP22 | |
| SCHEMBL5441685 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1BLMTDP1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4297723-B1 | MICRONEEDLE COMPOSITIONS AND METHODS OF DELIVERY USING THE SAME | BRIGHAM & WOMENS HOSPITAL INC (US) | 2026-05-20 | — | — | EP | claimed |
| US-20250277175-A1 | SINGLE-CHAMBER MICROBIAL ELECTROLYSIS CELL SYSTEM WITHOUT ION EXCHANGE MEMBRANE AND METHOD FOR PRODUCING CLEAN GAS SUCH AS HYDROGEN AND BIOGAS USING SAME | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2025-09-04 | — | — | US | claimed |
| WO-2025151713-A1 | PROTEIN AND PEPTIDE VACCINES TARGETING METHANOGENS | Arkea Bio Corp. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025151711-A1 | NUCLEIC ACID VACCINES TARGETING METHANOGENS | Arkea Bio Corp. (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250222082-A1 | PROTEIN AND PEPTIDE VACCINES TARGETING METHANOGENS | ARKEA BIO CORP (US) | 2025-07-10 | — | — | US | claimed |
| WO-2025128700-A1 | CELL-BASED VACCINES | Arkea Bio Corp. (US) | 2025-06-19 | — | — | WO | claimed |
| EP-4554616-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2025-05-21 | — | — | EP | claimed |
| US-20240424087-A1 | MULTIEPITOPE SELF-ASSEMBLED NANOPARTICLE VACCINE PLATFORM (MSN-VACCINE PLATFORM) AND USES THERE OF | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2024-12-26 | — | — | US | claimed |
| US-20240392324-A1 | Method for Microbiological Production of Hydrogen | CEMVITA FACTORY INC (US) | 2024-11-28 | — | — | US | claimed |
| WO-2024226815-A2 | B-CELL EPITOPES OF TREPONEMA PALLIDUM ANTIGENS FOR USE IN A SYPHILIS VACCINE | UNIVERSITY OF WASHINGTON (US) | 2024-10-31 | — | — | WO | claimed |
| WO-1994022449-A1 | THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-10-13 | — | — | WO | claimed |
| WO-1994016704-A1 | OXIME-SUBSTITUTED THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-08-04 | — | — | WO | claimed |
| WO-1994015605-A1 | ACETAL OR KETAL SUBSTITUTED THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-07-21 | — | — | WO | claimed |
| WO-1994015606-A1 | OLEFIN-SUBSTITUTED LONG CHAIN COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-07-21 | — | — | WO | claimed |
| WO-1994011370-A1 | SUBSTITUTED AMINO ALKYL COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | claimed |
| WO-1994011001-A1 | HYDROXYL-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | claimed |
| US-5278043-A | Chromophore compound | HOFFMANN-LA ROCHE INC. (US) | 1994-01-11 | — | — | US | claimed |
| EP-0566751-A1 | DNA detection method | F. HOFFMANN-LA ROCHE AG (CH) | 1993-10-27 | — | — | EP | claimed |
| EP-0468187-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1992-01-29 | — | — | EP | claimed |
| US-4082911-A | PROCESS FOR THE PREPARATION OF NUCLEOSIDES | SCHERING AKTIENGESELLSCHAFT (DT) | 1978-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222082-A1 | PROTEIN AND PEPTIDE VACCINES TARGETING METHANOGENS | MCRS1, VIP, HM13 | KDM4E 4403/4885ALDH1A1 4837/4885BLM 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.